In addition, reducing PABPN1 aggregation load through either oral treatment with anti-aggregation drugs, or expression of anti-PABPN1 intrabody improves muscle function in Drosophila and mouse OPMD models [30–34]. The gene discussed is PABPN1; the disease is oculopharyngeal muscular dystrophy.